Top entities: Asma Khalil, St George s, University of London, Kenvue, BMC Environmental Health, American College of Obstetricians and Gynecologists.

What category does this event fall under?

Tech — classified as scientific study.

What is the sentiment of coverage?

Aggregate sentiment score: 20 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Is this event still developing?

This event is archived — the story has concluded and this page is a final snapshot.

Tech scientific study

Study Debunks Paracetamol-Autism Link

Q: When did this event occur?

First reported Jan 16, 2026; last updated Jan 17, 2026.

Q: What is the market impact?

General. The new study published in The Lancet, refuting claims made by Donald Trump, is expected to reassure pregnant women and healthcare providers about the safety of paracetamol, potentially stabilizing demand for products from companies like Kenvue.

Analysis based on 23 articles · First reported Jan 16, 2026 · Last updated Jan 17, 2026

Sentiment

Attention

Articles

Market Impact

General

Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

Market Impact

The new study published in The Lancet, refuting claims made by Donald Trump, is expected to reassure pregnant women and healthcare providers about the safety of paracetamol, potentially stabilizing demand for products from companies like Kenvue. This scientific consensus could also reduce legal risks for pharmaceutical companies and reinforce the recommendations of medical organizations like the American College of Obstetricians and Gynecologists.

Pharmaceuticals Healthcare

Event Summary

A new comprehensive review of 43 studies, led by Asma Khalil and published in The Lancet Obstetrics, Gynecology & Women's Health, has found no credible evidence linking paracetamol (Tylenol) use during pregnancy to an increased risk of autism, ADHD, or intellectual disabilities in children. This research directly refutes claims made by Donald Trump in September 2025, who had urged pregnant women to avoid Tylenol due to unproven ties to autism. The study emphasizes that paracetamol remains a safe and recommended first-line treatment for pain and fever during pregnancy, with untreated fever posing greater risks to both mother and baby. The findings are supported by major medical organizations globally, including the American College of Obstetricians and Gynecologists and the United Kingdom — National Health Service in the United Kingdom, and aim to alleviate public confusion caused by misinformation.

Entities Involved

per

Asma Khalil

Asma Khalil is the lead author of the comprehensive review published in The Lancet Obstetrics, Gynecology & Women's Health, which found no link between paracetamol use in pregnancy and neurodevelopmental disorders. Her research provides reassurance regarding the drug's safety.

Importance 90.0 Sentiment 70.0

oth

St George s, University of London

St George s, University of London was the lead institution for the international research, contributing significantly to the study's methodology and findings.

Importance 70.0 Sentiment 50.0

stock

Kenvue

Kenvue, the manufacturer of Tylenol (paracetamol), faced a lawsuit regarding alleged links between its product and autism, which was dismissed. The new study supports the safety of its product.

Importance 60.0 Sentiment 20.0

oth

BMC Environmental Health

A paper published in BMC Environmental Health, which supported an association between Tylenol exposure during pregnancy and increased incidence of neurodevelopmental disorders, is now contrasted by the new, more rigorous study.

Importance 10.0 Sentiment 0.0

ngo

American College of Obstetricians and Gynecologists